Available via license: CC BY 4.0
Content may be subject to copyright.
Oodles of opportunities: the Journal of Cachexia,
Sarcopenia and Muscle in 2017
Stephan von Haehling
1
*, Nicole Ebner
1
& Stefan D. Anker
2
1
Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany;
2
Division of Cardiology and Metabolism—Heart Failure, Cachexia
& Sarcopenia, Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT); Deutsches Zentrum für Her z-Kreislauf-Forschung (DZHK)
Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany
Received: 28 August 2017; Accepted: 31 August 2017
*Correspondence to: Dr Stephan von Haehling, MD PhD FESC, Department of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Strasse 40,
D-37075 Göttingen, Germany. Tel.: +49 551 39 20911; Fax: +49 551 39 20918. Email: stephan.von.haehling@web.de
The good news first, the Journal of Cachexia, Sarcopenia
and Muscle (JCSM) has not only maintained its impact
factor, but it has even increased it again, now reaching
9.697 as has been published by Thomson Scientific a few
weeks ago. To obtain a grip of the impact factor, it has
to be acknowledged that it requires calculation of cites to
items published in 2014 and 2015 divided by the number
of items published in 2014 and 2015. In numbers, we
reached a total of 368 cites in 2014 and 272 cites in
2015, summing up to 640 cites in total. This may not seem
a lot, but considering that we only published 66 items
deemed countable (editorial comments and letters-to-the-
editor are not counted), the final impact factor reached
9.697, implying that each of our papers are cited almost
10 times over the course of 2 years. This places JCSM as
the number 8 ranked journal among all journals in the
category ‘Medicine, General and Internal’(Table 1) and as
number 2 ranking publication among all nutrition journals,
among which, however, JCSM is still not officially listed by
Thomson Scientific (Table 2).
As we have done before and are not getting tired of, we
herewith express our gratitude to all authors, reviewers,
and editorial board members for their great efforts to pro-
duce JCSM at good quality, and we greatly appreciate and
value also the interest and support of all those who enjoy
reading JCSM and cite the papers published there. Of course,
the Journal would not be what it is without our editorial office
team Monika Diek and Corinna Denecke, and we would also
like to express our thanks for their professional support!
This year is special to JCSM for several reasons. One is the
publication of additional issues this year, the other is the
inauguration of our two daughter journals. Indeed, JCSM
appears to have sparked more scientific interest in the field
of body wasting, cachexia, and sarcopenia, and thus the
number of submissions to the main journal remains on the
increase. With a 73% rejection rate, we are well aware of
the fact that we have to decline publication of many good
papers, simply for lack of space. However, we do hope that
we are able to give some of these a home in our daughter
journals—JCSM Rapid Communications and JCSM Clinical
Reports. The latter is online already since December 2016,
and a good number of original research papers has been
published since. At the time of writing this editorial in August
2017, the main journal, JCSM, has received already 187
submissions in 2017 alone, proving a steady increase in
submissions: last year, this number was ‘only’158. Given
these higher numbers of submissions, in 2017 we will move
to six issues per year to allow publication of more accepted
papers.
We are working hard to provide a timely peer review,
which is not always easy, as it is difficult to find appropri-
ate reviewers at times. Articles that are available for the
longest time are—not surprisingly—those that have been
cited most (Table 3). Our ‘facts and numbers’editorials
remain popular (Tables 4 and 5), and we invite our
readers to submit their work or to suggest topics for ‘facts
and numbers’editorials that are relevant to our readers
(Table 6).
Finally, we would like to draw attention to the upcoming
Cachexia Conference to be held between December 8–10,
2017 in Rome, Italy. The conference became an annual
meeting already 2 years ago, and it is a source of stimulat-
ing ideas and exchange between clinicians and researchers
in the field of cachexia and wasting. Data on the final pro-
EDITORIAL
© 2017 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 675–680
Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/jcsm.12247
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
gram and more information is to be found at http://society-
scwd.org.
Acknowledgement
The authors certify that they comply with the ethical
guidelines for authorship and publishing of the Journal of
Cachexia, Sarcopenia and Muscle.
71
Table 1. Top 10 journals in the field ‘medicine: General & Internal’
Impact Items Issues
Journal name factor published per
2017 2015 and 2016 Year
1 New England Journal
of Medicine
72.406 670 52
2 Lancet 47.831 646 52
3 Journal of the American
Medical Association (JAMA)
44.405 410 48
4 British Medical Journal 20.785 446 52
5 Annals of Internal Medicine 17.135 150 24
6 JAMA Internal Medicine 16.538 275 12
7 PLOS Medicine 11.862 286 12
8 Journal of Cachexia,
Sarcopenia and Muscle
9.697 88 4
9 BMC Medicine 7.901 418
10 Journal of Internal
Medicine
7.598 194 12
Table 2. Top 10 journals in the field ‘Nutrition & Dietetics’, where the
Journal of Cachexia, Sarcopenia and Muscle is officially not listed
Impact Items Issues
Journal name factor published per
2017 2015 and 2016 Year
1 Progress in Lipid Research 10.583 69 4
2 Annuals Review of Nutrition 9.054 44 1
3 American Journal of Clinical
Nutrition
6.926 649 12
4 Critical Reviews in Food
Science and Nutrition
6.077 149 12
5 International Journal of Obesity 5.487 502 12
6 Nutrition Reviews 5.291 132 12
7 Advances in Nutrition 5.233 177 6
8 Nutrition Research Reviews 4.844 29 2
9 Clinical Nutrition 4.548 375 6
10 Food Chemistry 4.529 3547 24
Table 3. Top 10 of best cited articles since first publication of the Journal
of Cachexia, Sarcopenia and Muscle
First
Author Title Type Year
Times
Cited Reference
1 von
Haehling
Cachexia as a
major
underestimated
and unmet
medical need:
facts and
numbers
Editorial 2010 203
1
2 von
Haehling
An overview of
sarcopenia: facts
and numbers on
prevalence and
clinical impact
Editorial 2010 125
2
3 Dalton The selective
androgen
receptor
modulator
Original
article
2011 111
3
(Continues)
Table 3 (continued)
First
Author Title Type Year
Times
Cited Reference
GTx-024
(enobosarm)
improves lean
body mass
and physical
function in
healthy elderly
men and
postmenopausal
women: results
of a double-
blind, placebo-
controlled phase
II trial
4 Morley From Sarcopenia
to frailty: a road
less travelled
Editorial 2014 94
4
5 Lenk Skeletal muscle
wasting in
cachexia and
sarcopenia:
molecular
pathophysiology
and impact of
exercise training
Review 2010 90
5
6 Fanzani Molecular and
cellular
mechanisms of
skeletal muscle
atrophy: an
update
Review 2012 78
6
7 Elkina The role of
myostatin in
muscle wasting:
an overview.
Review 2011 75
7
8 Cesari Biomarkers of
sarcopenia in
clinical trials-
recommendations
from the
International
Working Group
on Sarcopenia
Original
article
2012 72
8
9 Mak Wasting in
chronic kidney
disease
Review 2011 67
9
10 von
Haehling
From muscle
wasting to
sarcopenia and
myopenia:
update 2012
Editorial 2012 63
10
676 Editorial
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 675–680
DOI: 10.1002/jcsm.12247
Table 4. Top 20 of best cited articles published 2014 in the Journal of Cachexia, Sarcopenia and Muscle
First Author Title Type Times cited Reference
1 Wakabayashi Rehabilitation nutrition for sarcopenia with disability: a combination of
both rehabilitation and nutrition care management
Review 79
11
2 von
Haehling
Prevalence, incidence, and clinical impact of cachexia: facts and numbers
—update 2014
Editorial 75
12
3 Morley Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers,
and epidemiology—update 2014
Editorial 69
13
4 Morley From sarcopenia to frailty: a road less travelled Editorial 59
4
5 Ormsbee Osteosarcopenic obesity: the role of bone, muscle, and fat on health Review 39
14
6 Heymsfield Assessing skeletal muscle mass: historical overview and state of the art Review 37
15
7 Morley Are we closer to having drugs to treat muscle wasting disease? Editorial 36
16
8 Anker Muscle wasting disease: a proposal for a new disease classification Editorial 27
17
9 Ebner Highlights from the 7th Cachexia Conference: muscle wasting
pathophysiological detection and novel treatment strategies
Meeting Report 26
18
10 Pietra Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the
treatment of cancer anorexia-cachexia syndrome: preclinical profile
Original Article 26
19
11 Fragala Biomarkers of muscle quality: N-terminal propeptide of type III procollagen
and C-terminal agrin fragment responses to resistance exercise training in
older adults
Original Article 25
20
12 Palus Muscle wasting: an overview of recent developments in basic research Review 20
21
13 Josiak Skeletal myopathy in patients with chronic heart failure: significance of
anabolic-androgenic hormones
Review 20
22
14 Toledo Formoterol in the treatment of experimental cancer cachexia: effects on
heart function
Original Article 19
23
15 Alchin Sarcopenia: describing rather than defining a condition Review 17
24
16 Argiles Cachexia: a problem of energetic inefficiency Review 16
25
17 Rhee Resistance exercise: an effective strategy to reverse muscle wasting in
hemodialysis patients?
Editorial 15
26
18 Khawaja Ventricular assist device implantation improves skeletal muscle function,
oxidative capacity, and growth hormone/insulin-like growth factor-1
axis signalling in patients with advanced heart failure
Original Article 15
27
19 Mirza Attenuation of muscle wasting in murine C2C12 myotubes by
epigallocatechin-3-gallate
Original Article 15
28
20 Kirkman Anabolic exercise in haemodialysis patients: a randomized controlled
pilot study
Original Article 13
29
Table 5. Top 20 of best cited articles published 2015 in the Journal of Cachexia, Sarcopenia and Muscle
First Author Title Type Times cited Reference
1 Calvani Biomarkers for physical frailty and sarcopenia: state of the science and future
developments
Review 37
30
2 Bowen Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology
and impact of exercise training
Review 36
31
3 Ezeoke Pathophysiology of anorexia in the cancer cachexia syndrome Review 28
32
4 Fearon Request for regulatory guidance for cancer cachexia intervention trials Editorial 24
33
5 Chen Ghrelin prevents tumour-induced and cisplatin-induced muscle wasting:
characterization of multiple mechanisms involved
Original Article 17
34
6 Manger Skeletal muscle alterations in chronic heart failure: differential effects
on quadriceps and diaphragm
Original Article 17
35
7 Grande Exercise for cancer cachexia in adults: Executive summary of a
Cochrane Collaboration systematic review
Review 16
36
8 Sasso A framework for prescription in exercise-oncology research Editorial 14
37
9 Cvan Trobec Influence of cancer cachexia on drug liver metabolism and
renal elimination in rats
Original Article 13
38
10 Dupuy Searching for a relevant definition of sarcopenia: results from the
cross-sectional EPIDOS study
Original Article 13
39
11 Morley Rapid screening for sarcopenia Editorial 12
40
12 Stephens Evaluating potential biomarkers of cachexia and survival in
skeletal muscle of upper gastrointestinal cancer patients
Original Article 11
41
13 Faber Improved body weight and performance status and
reduced serum PGE2 levels after nutritional intervention with
a specific medical food in newly diagnosed patients with
esophageal cancer or adenocarcinoma of the gastro-esophageal junction
Original Article 10
42
(Continues)
Editorial 677
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 675–680
DOI: 10.1002/jcsm.12247
Table 5 (continued)
First Author Title Type Times cited Reference
14 Drescher Loss of muscle mass: current developments in cachexia and sarcopenia focused
on biomarkers and treatment
Review 8
43
15 Wakabayashi Skeletal muscle mass is associated with severe dysphagia in cancer patients Original Article 8
44
16 Dev Hypermetabolism and symptom burden in advanced cancer patients evaluated
in a cachexia clinic
Original Article 6
45
17 Cooper Understanding and managing cancer-related weight loss and anorexia:
insights from a systematic review of qualitative research
Review 6
46
18 Marino Activin-βC modulates cachexia by repressing the ubiquitin-proteasome and
autophagic degradation pathways
Original Article 6
47
19 Haruta One-year intranasal application of growth hormone releasing peptide-2
improves body weight and hypoglycemia in a severely emaciated anorexia
nervosa patient
Original Article 5
48
20 van Norren Behavioural changes are a major contributing factor in the reduction of
sarcopenia in caloric-restricted ageing mice
Original Article 5
49
Table 6. Top 20 of best cited articles published 2016 in the Journal of Cachexia, Sarcopenia and Muscle
First Author Title Type Times cited Reference
1 Malmstrom SARC-F: a symptom score to predict persons with sarcopenia at risk for poor
functional outcomes
Original Article 33
50
2 Tyrovolas Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic
obesity in older adults: a multi-continent study
Original Article 12
51
3 Sakuma p62/SQSTM1 but not LC3 is accumulated in sarcopenic muscle of mice Original Article 9
52
4 Loncar Cardiac cachexia: hic et nunc Review 8
53
5 Go Prognostic impact of sarcopenia in patients with diffuse large B-cell
lymphoma treated with rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone
Original Article 6
54
6 de Lima Doxorubicin caused severe hyperglycaemia and insulin resistance,
mediated by inhibition in AMPK signalling in skeletal muscle
Original Article 6
55
7 Lodka Muscle RING-fingers 2 and 3 maintain striated-muscle structure and function Original Article 5
56
8 Lewis Increased expression of H19/miR-675 is associated with a low fat-free mass
index in patients with COPD
Original Article 5
57
9 Montano-Loza Sarcopenic obesity and myosteatosis are associated with higher mortality
in patients with cirrhosis
Original Article 4
58
10 Barbosa-Silva Prevalence of sarcopenia among community-dwelling elderly of a
medium-sized South American city: results of the COMO VAI? study
Original Article 4
59
11 Penna Effect of the specific proteasome inhibitor bortezomib on cancer-related
muscle wasting
Original Article 4
60
12 Vries Patient-centred physical therapy is (cost-) effective in increasing physical
activity and reducing frailty in older adults with mobility problems: a
randomized controlled trial with 6 months follow-up
Original Article 4
61
13 Batista Cachexia-associated adipose tissue morphological rearrangement in
gastrointestinal cancer patients
Original Article 3
62
14 Giron Conversion of leucine to β-hydroxy-β-methylbutyrate by α-keto isocaproate
dioxygenase is required for a potent stimulation of protein synthesis in L6
rat myotubes
Original Article 3
63
15 Lainscak ACT-ONE-ACTION at last on cancer cachexia by adapting a novel action
beta-blocker
Editorial 3
64
16 Berger Dysfunction of respiratory muscles in critically ill patients on the
intensive care unit
Review 3
65
17 Musolino Megestrol acetate improves cardiac function in a model of cancer
cachexia-induced cardiomyopathy by autophagic modulation
Original Article 3
66
18 Neves White adipose tissue cells and the progression of cachexia: inflammatory
pathways
Original Article 2
67
19 Polge UBE2B is implicated in myofibrillar protein loss in catabolic C2C12 myotubes Original Article 2
68
20 Pinto Impact of creatine supplementation in combination with resistance
training on lean mass in the elderly
Original Article 2
69
678 Editorial
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 675–680
DOI: 10.1002/jcsm.12247
References
1. von Haehling S, Anker SD. Cachexia as a
major underestimated and unmet medical
need: facts and numbers. J Cachexia
Sarcopenia Muscle 2010;1:1–5.
2. von Haehling S, Morley JE, Anker SD. An
overview of sarcopenia: facts and numbers
on prevalence and clinical impact. J Ca-
chexia Sarcopenia Muscle 2010;1:129–133.
3. Dalton JT, Barnette KG, Bohl CE, Hancock
ML, Rodriguez D, Dodson ST, et al. The se-
lective androgen receptor modulator GTx-
024 (enobosarm) improves lean body mass
and physical function in healthy elderly
men and postmenopausal women: results
of a double-blind, placebo-controlled phase
II trial. J Cachexia Sarcopenia Muscle 2011;
2:153–161.
4. Morley JE, von Haehling S, Anker SD, Vellas
B. From sarcopenia to frailty: a road less
traveled. J Cachexia Sarcopenia Muscle.
2014;5:5–8.
5. Lenk K, Schuler G, Adams V. Skeletal mus-
cle wasting in cachexia and sarcopenia:
molecular pathophysiology and impact of
exercise training. J Cachexia Sarcopenia
Muscle 2010;1:9–21.
6. Fanzani A, Conraads VM, Penna F, Martinet
W. Molecular and cellular mechanisms of
skeletal muscle atrophy: an updatee. J Ca-
chexia Sarcopenia Muscle 2012;3:163–179.
7. Elkina Y, von Haehling S, Anker SD, Springer
J. The role of myostatin in muscle wasting:
an overview. J Cachexia Sarcopenia Muscle
2011;2:143–151.
8. Cesari M, Fielding RA, Pahor M, Goodpaster
B, Hellerstein M, van Kan GA, et al. for the
International Working Group on Sarcopenia.
Biomarkers of sarcopenia in clinical trials-
recommendations from the International
Working Group on Sarcopenia. JCachexia
Sarcopenia Muscle 2012; 3:181–90.
9. Mak RH, Ikizler AT, Kovesdy CP, Raj DS,
Stenvinkel P, Kalantar-Zadeh K. Wasting in
chronic kidney disease. J Cachexia Sarcopenia
Muscle 2011;2:9–25.
10. von Haehling S, Morley JE, Anker SD. From
muscle wasting to sarcopenia and
myopenia: update 2012. J Cachexia
Sarcopenia Muscle. 2012;3:213–217.
11. Wakabayashi H, Sakuma K. Rehabilitation
nutrition for sarcopenia with disability: a
combination of both rehabilitation and nu-
trition care management. J Cachexia
Sarcopenia Muscle 2014;5:269–277.
12. von Haehling S, Anker SD. Prevalence, inci-
dence and clinical impact of cachexia: facts
and numbers—update 2014. J Cachexia
Sarcopenia Muscle. 2014;5:261–263.
13. Morley JE, Anker SD, von Haehling S. Prev-
alence, incidence, and clinical impact of
sarcopenia: facts, numbers, and epidemiol-
ogy—update 2014. J Cachexia Sarcopenia
Muscle. 2014;5:253–259.
14. Ormsbee MJ, Prado CM, Ilich JZ, Purcell S,
Siervo M, Folsom A, et al. Osteosarcopenic
obesity: the role of bone, muscle, and fat
on health. J Cachexia Sarcopenia Muscle.
2014;5:183–92.
15. Heymsfield SB, Adamek M, Gonzalez MC,
Jia G, Thomas DM. Assessing skeletal mus-
cle mass: historical overview and state of
the art. J Cachexia Sarcopenia Muscle.
2014;5:9–18.
16. Morley JE, von Haehling S, Anker SD. Are
we closer to having drugs to treat muscle
wasting disease? J Cachexia Sarcopenia
Muscle. 2014;5:83–87.
17. Anker SD, Coats AJ, Morley JE, Rosano G,
Bernabei R, von Haehling S, et al. Muscle
wasting disease: a proposal for a new dis-
ease classification. J Cachexia Sarcopenia
Muscle. 2014;5:1–3.
18. Ebner N, Steinbeck L, Doehner W, Anker
SD, von Haehling S. Highlights from the
7th Cachexia Conference: muscle wasting
pathophysiological detection and novel
treatment strategies. J Cachexia
Sarcopenia Muscle. 2014;5:27–34.
19. Pietra C, Takeda Y, Tazawa-Ogata N,
Minami M, Yuanfeng X, Duus EM, et al.
Anamorelin HCl (ONO-7643), a novel
ghrelin receptor agonist, for the treatment
of cancer anorexia-cachexia syndrome:
preclinical profile. J Cachexia Sarcopenia
Muscle. 2014;5:329–37.
20. Fragala MS, Jajtner AR, Beyer KS,
Townsend JR, Emerson NS, Scanlon TC,
et al. Biomarkers of muscle quality: N-
terminal propeptide of type III procollagen
and C-terminal agrin fragment responses
to resistance exercise training in older
adults. J Cachexia Sarcopenia Muscle.
2014;5:139–48.
21. Palus S, von Haehling S, Springer J. Muscle
wasting: an overview of recent develop-
ments in basic research. J Cachexia
Sarcopenia Muscle 2014;5:193–198.
22. Josiak K, Jankowska EA, Piepoli MF,
Banasiak W, Ponikowski P. Skeletal myopa-
thy in patients with chronic heart failure:
significance of anabolic-androgenic hor-
mones. J Cachexia Sarcopenia Muscle.
2014;5:287–296.
23. Toledo M, Springer J, Busquets S, Tschirner
A, López-Soriano FJ, Anker SD, et al.
Formoterol in the treatment of experimen-
tal cancer cachexia: effects on heart
function. J Cachexia Sarcopenia Muscle
2014;5:315–20.
24. Alchin DR. Sarcopenia: describing rather
than defining a condition. J Cachexia
Sarcopenia Muscle 2014;5:265–268.
25. Argilés JM, Fontes-Oliveira CC, Toledo M,
López-Soriano FJ, Busquets S. Cachexia: a
problem of energetic inefficiency. J Ca-
chexia Sarcopenia Muscle 2014;5:279–286.
26. Rhee CM, Kalantar-Zadeh K. Resistance exer-
cise: an effective strategy to reverse muscle
wasting in hemodialysis patients? JCachexia
Sarcopenia Muscle 2014;5:177–180.
27. Khawaja T, Chokshi A, Ji R, Kato TS, Xu K,
Zizola C, et al.Ventricular assist device im-
plantation improves skeletal muscle func-
tion, oxidative capacity, and growth
hormone/insulin-like growth factor-1 axis
signaling in patients with advanced heart
failure. J Cachexia Sarcopenia Muscle
2014;5:297–305.
28. Mirza KA, Pereira SL, Edens NK, Tisdale MJ.
Attenuation of muscle wasting in murine
C2C 12 myotubes by epigallocatechin-3-
gallate. J Cachexia Sarcopenia Muscle
2014;5:339–345.
29. Kirkman DL, Mullins P, Junglee NA,
Kumwenda M, Jibani MM, Macdonald JH.
Anabolic exercise in haemodialysis patients:
a randomised controlled pilot study. JCa-
chexia Sarcopenia Muscle 2014;5:199–207.
30. Calvani R, Marini F, Cesari M, Tosato M,
Anker SD, von Haehling S, et al.; SPRINTT
consortium. Biomarkers for physical frailty
and sarcopenia: state of the science and fu-
ture developments J Cachexia Sarcopenia
Muscle. 2015;6:278–86.
31. Bowen TS, Schuler G, Adams V. Skeletal
muscle wasting in cachexia and sarcopenia:
molecular pathophysiology and impact of
exercise training. J Cachexia Sarcopenia
Muscle. 2015;6:197–207.
32. Ezeoke CC, Morley JE. Pathophysiology of
anorexia in the cancer cachexia syndrome.
J Cachexia Sarcopenia Muscle.
2015;6:287–302.
33. Fearon K, Argiles JM, Baracos VE, Bernabei
R, Coats A, Crawford J, et al. Request for
regulatory guidance for cancer cachexia in-
tervention trials. J Cachexia Sarcopenia
Muscle. 2015;6:272–4.
34. Chen JA, Splenser A, Guillory B, Luo J,
Mendiratta M, Belinova B, et al. Ghrelin
prevents tumour- and cisplatin-induced
muscle wasting: characterization of multi-
ple mechanisms involved. J Cachexia
Sarcopenia Muscle. 2015;6:132–43.
35. Henwood TR, Keogh JW, Reid N, Jordan W,
Senior HE. Assessing sarcopenic prevalence
and risk factors in residential aged care:
methodology and feasibility. J Cachexia
Sarcopenia Muscle. 2014;5:229–236.
36. Grande AJ, Silva V, Maddocks M. Exercise
for cancer cachexia in adults: Executive
summary of a Cochrane Collaboration sys-
tematic review. J Cachexia Sarcopenia Mus-
cle. 2015;6:208–211.
37. Sasso JP, Eves ND, Christensen JF, Koelwyn
GJ, Scott J, Jones LW. A framework for pre-
scription in exercise-oncology research. J
Cachexia Sarcopenia Muscle.
2015;6:115–124.
38. Cvan Trobec K, Kerec Kos M, Trontelj J,
Grabnar I, Tschirner A, Palus S, et al. Influ-
ence of cancer cachexia on drug liver me-
tabolism and renal elimination in rats. J
Cachexia Sarcopenia Muscle. 2015;6:
45–52.
39. Dupuy C, Lauwers-Cances V, Guyonnet S,
Gentil C, Abellan Van Kan G, Beauchet O,
et al. Searching for a relevant definition
of sarcopenia: results from the cross-
sectional EPIDOS study. J Cachexia
Sarcopenia Muscle. 2015;6:144–54.
40. Morley JE, Cao L. Rapid screening for
sarcopenia. J Cachexia Sarcopenia Muscle.
2015;6:312–314.
Editorial 679
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 675–680
DOI: 10.1002/jcsm.12247
41. Stephens NA, Skipworth RJ, Gallagher IJ,
Greig CA, Guttridge DC, Ross JA, et al. Eval-
uating potential biomarkers of cachexia
and survival in skeletal muscle of upper
gastrointestinal cancer patients. J Cachexia
Sarcopenia Muscle. 2015;6:53–61.
42. Faber J, Uitdehaag MJ, Spaander M, van
Steenbergen-Langeveld S, Vos P, Berkhout
M, et al. Improved body weight and perfor-
mance status and reduced serum PGE(2)
levels after nutritional intervention with a
specific medical food in newly diagnosed
patients with esophageal cancer or adeno-
carcinoma of the gastro-esophageal junc-
tion. J Cachexia Sarcopenia Muscle. 2015;
6:32–44.
43. Drescher C, Konishi M, Ebner N, Springer J.
Loss of muscle mass: current develop-
ments in cachexia and sarcopenia focused
on biomarkers and treatment. J Cachexia
Sarcopenia Muscle. 2015;6:303–311.
44. Wakabayashi H, Matsushima M, Uwano R,
Watanabe N, Oritsu H, Shimizu Y. Skeletal
muscle mass is associated with severe dys-
phagia in cancer patients. J Cachexia
Sarcopenia Muscle. 2015;6:351–357.
45. Dev R, Hui D, Chisholm G, Delgado-Guay
M, Dalal S, Del Fabbro E, et al. Hyperme-
tabolism and symptom burden in advanced
cancer patients evaluated in a cachexia
clinic. J Cachexia Sarcopenia Muscle.
2015;6:95–8.
46. Cooper C, Burden ST, Cheng H, Molassiotis
A. Understanding and managing cancer-
related weight loss and anorexia: insights
from a systematic review of qualitative re-
search. J Cachexia Sarcopenia Muscle.
2015;6:99–111.
47. Marino FE, Risbridger G, Gold E. Activin-βC
modulates cachexia by repressing the
ubiquitin-proteasome and autophagic deg-
radation pathways. J Cachexia Sarcopenia
Muscle. 2015;6:365–380.
48. Haruta I, Fuku Y, Kinoshita K, Yoneda K,
Morinaga A, Amitani M, et al. One-year in-
tranasal application of growth hormone re-
leasing peptide-2 improves body weight
and hypoglycemia in a severely emaciated
anorexia nervosa patient. J Cachexia
Sarcopenia Muscle. 2015;6:237–41.
49. van Norren K, Rusli F, van Dijk M, Lute C,
Nagel J, Dijk FJ, et al. Behavioural changes
are a major contributing factor in the re-
duction of sarcopenia in caloric-restricted
ageing mice. J Cachexia Sarcopenia Muscle.
2015;6:253–68.
50. Malmstrom TK, Miller DK, Simonsick EM,
Ferrucci L, Morley JE. SARC-F: a symptom
score to predict persons with sarcopenia
at risk for poor functional outcomes. J Ca-
chexia Sarcopenia Muscle. 2016;7:28–36.
51. Tyrovolas S, Koyanagi A, Olaya B, Ayuso-
Mateos JL, Miret M, Chatterji S, et al. Fac-
tors associated with skeletal muscle mass,
sarcopenia, and sarcopenic obesity in older
adults: a multi-continent study. J Cachexia
Sarcopenia Muscle. 2016;7:312–21.
52. Sakuma K, Kinoshita M, Ito Y, Aizawa M,
Aoi W, Yamaguchi A. p62/SQSTM1 but
not LC3 is accumulated in sarcopenic mus-
cle of mice. J Cachexia Sarcopenia Muscle.
2016;7:204–212.
53. Loncar G, Springer J, Anker M, Doehner W,
Lainscak M. Cardiac cachexia: hic et nunc. J
Cachexia Sarcopenia Muscle.
2016;7:246–260.
54. Go SI, Park MJ, Song HN, Kim HG, Kang MH,
Lee HR, et al. Prognostic impact of
sarcopenia in patients with diffuse large
B-cell lymphoma treated with rituximab
plus cyclophosphamide, doxorubicin, vin-
cristine, and prednisone. J Cachexia
Sarcopenia Muscle. 2016;7:567–576.
55. de Lima Junior EA, Yamashita AS, Pimentel
GD, De Sousa LG, Santos RV, Gonçalves
CL, et al. Doxorubicin caused severe
hyperglycaemia and insulin resistance, me-
diated by inhibition in AMPk signalling in
skeletal muscle. J Cachexia Sarcopenia
Muscle. 2016;7:615–625.
56. Lodka D, Pahuja A, Geers-Knörr C, Scheibe
RJ, Nowak M, Hamati J, et al. Muscle
RING-finger 2 and 3 maintain striated-
muscle structure and function. J Cachexia
Sarcopenia Muscle. 2016;7:165–80.
57. Lewis A, Lee JY, Donaldson AV, Natanek SA,
Vaidyanathan S, Man WD, et al. Increased
expression of H19/miR-675 is associated
with a low fat-free mass index in patients
with COPD. J Cachexia Sarcopenia Muscle.
2016;7:330–44.
58. Montano-Loza AJ, Angulo P, Meza-Junco J,
Prado CM, Sawyer MB, Beaumont C, et al.
Sarcopenic obesity and myosteatosis are
associated with higher mortality in patients
with cirrhosis. J Cachexia Sarcopenia Mus-
cle. 2016;7:126–35.
59. Barbosa-Silva TG, Bielemann RM, Gonzalez
MC, Menezes AM. Prevalence of
sarcopenia among community-dwelling el-
derly of a medium-sized South American
city: results of the COMO VAI? study. J Ca-
chexia Sarcopenia Muscle.
2016;7:136–143.
60. Penna F, Bonetto A, Aversa Z, Minero VG,
Rossi Fanelli F, Costelli P, et al. Effect of
the specific proteasome inhibitor
bortezomib on cancer-related muscle
wasting. J Cachexia Sarcopenia Muscle.
2016;7:345–54.
61. de Vries NM, Staal JB, van der Wees PJ,
Adang EM, Akkermans R, Olde Rikkert
MG, et al. Patient-centred physical therapy
is (cost-) effective in increasing physical ac-
tivity and reducing frailty in older adults
with mobility problems: a randomized con-
trolled trial with 6 months follow-up. J Ca-
chexia Sarcopenia Muscle. 2016;7:422–35.
62. Batista ML Jr, Henriques FS, Neves RX,
Olivan MR, Matos-Neto EM, Alcântara PS,
et al. Cachexia-associated adipose tissue
morphological rearrangement in gastroin-
testinal cancer patients. J Cachexia
Sarcopenia Muscle. 2016;7:37–47.
63. Girón MD, Vílchez JD, Salto R, Manzano M,
Sevillano N, Campos N, et al. Conversion of
leucine to β-hydroxy-β-methylbutyrate by
α-keto isocaproate dioxygenase is required
for a potent stimulation of protein synthe-
sis in L6 rat myotubes. J Cachexia
Sarcopenia Muscle. 2016;7:68–78.
64. Lainscak M, Laviano A. ACT-ONE-ACTION at
last on cancer cachexia by adapting a novel
action beta-blocker. J Cachexia Sarcopenia
Muscle. 2016;7:400–402.
65. Berger D, Bloechlinger S, von Haehling S,
Doehner W, Takala J, Z’Graggen WJ, et al.
Dysfunction of respiratory muscles in criti-
cally ill patients on the intensive care unit.
J Cachexia Sarcopenia Muscle. 2016;7:
403–12.
66. Musolino V, Palus S, Tschirner A, Drescher
C, Gliozzi M, Carresi C, et al. Megestrol ac-
etate improves cardiac function in a model
of cancer cachexia-induced cardiomyopa-
thy by autophagic modulation. J Cachexia
Sarcopenia Muscle. 2016;7:555–566.
67. Neves RX, Rosa-Neto JC, Yamashita AS,
Matos-Neto EM, Riccardi DM, Lira FS,
et al. White adipose tissue cells and the
progression of cachexia: inflammatory
pathways. J Cachexia Sarcopenia Muscle
2016;7:193–203.
68. Polge C, Leulmi R, Jarzaguet M, Claustre A,
Combaret L, Béchet D, et al. UBE2B is im-
plicated in myofibrillar protein loss in cata-
bolic C2C12 myotubes. J Cachexia
Sarcopenia Muscle. 2016;7:377–87.
69. Pinto CL, Botelho PB, Carneiro JA, Mota JF.
Impact of creatine supplementation in
combination with resistance training on
lean mass in the elderly. J Cachexia
Sarcopenia Muscle. 2016;7:413–421.
70. www.webofknowledge.com (accessed
08/08/2017).
71. von Haehling S, Morley JE, Coats AJS, Anker
SD. Ethical guidelines for authorship and
publishing in the Journal of Cachexia,
Sarcopenia and Muscle. J Cachexia
Sarcopenia Muscle 2015;4:315–316.
680 Editorial
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 675–680
DOI: 10.1002/jcsm.12247
